Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

CAP TODAY Webinars

Multicenter Evaluation of Next-Day CGP Using the Oncomine™ Comprehensive Assay Plus on the Genexus™ System-April 28, 2026

Webinar presenters Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark, discuss how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Automated and integrated genomic profiling of hematologic malignancies-March 5, 2026

Join David Gonzalez, PhD, FRCPath, one of the leading experts in the EuroClonality-NGS working group of the Euroclonality consortium, dedicated to advancing standardized diagnostics in hematology-oncology, to learn:

• How EuroClonality-NDC and Myeloid-NDC NGS Workflows are utilized in advancing the future of diagnostics, prognostics, and targeted therapies.

• How these revolutionary assays provide comprehensive genomic data that reveals mutations, structural variations, and clonal evolution patterns with remarkable resolution, enabling clinical researchers to delve deeper into the genomic landscape of hematological malignancies.

From Cough to Critical: The Role of Syndromic Respiratory Testing Across the Care Continuum-January 21, 2026


Webinar presenters Shyam M. Sivasankar, MD, FAAP, FACEP, Associate Trauma Medical Director & Assistant Professor, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, and Dan Feinstein, MD, FACP, Director of Pulmonary Critical Care Medicine, Triad Region; System-wide Director, TeleICU & Co-Director, Sepsis, Novant Health, team up for this session bringing together two physicians—one representing inpatient and critical care from a large health system, and the other offering a perspective on urgent and near-patient care—to share how syndromic polymerase chain reaction (PCR) testing informs real-world patient management.

Unlocking Fertility Insights: The Power of AMH in Reproductive Health-September 24, 2025


Webinar presenters Wendy Vitek, MD, Board-certified Reproductive Endocrinologist, Boston IVF’s Syracuse, NY Fertility Center, and Shirley Li, MD, PhD, Associate Professor-Clinical, Department of Pathology; Director of Clinical Pathology Services and Co-Director of the Clinical Chemistry & Toxicology Laboratory, The Ohio State University, explore Anti-Müllerian Hormone (AMH) from both analytical and clinical perspectives.

Pathologist Perspectives: Experience Leveraging the Genius® Digital Diagnostics System for Digital Cytology-October 29, 2025


Webinar presenters Liron Pantanowitz, MD, PhD, MHA, Chair and Maud Menten Professor of Pathology, UPMC/University of Pittsburgh UPMC Shadyside Hospital, and Richard Lozano, MD, President, P&C Labs, LLC. and Vice President, Chipps, Caffrey, Dubilier, and PSC, discuss their experience with the Genius Digital Diagnostics System and data leveraging digital cytology for cervical cancer screening.

Introduction of a new FDA approved rapid NGS solution for Companion Diagnostics and tumor profiling in oncology-August 27, 2025


Webinar presenters David Chi, PhD, Director of Oncology Product Management, Thermo Fisher Scientific, and Gary Pestano, PhD, Chief Development Officer, Biodesix, Inc., and Bence Sipos, MD, Molecular Pathology, Baden-Württemberg, Stuttgart, Germany, discusses the rapidly evolving field of precision oncology, the increasing availability of targeted treatments offers renewed hope to patients.

Amplicon-based NGS panels in clinical practice: From broad oncology applications to advancing breast cancer care-June 17, 2025


Webinar presenters Emilie Lalonde, PhD, FACMG, Molecular Geneticist and Cytogeneticist, Molecular Diagnostics Division, PaLM, London Health Sciences Centre and St. Joseph’s Health Care, Assistant Professor, Pathology and Laboratory Medicine, Western University, and Cheryl A. Mather, MD Medical Director, Molecular Pathology (North Sector), Alberta Precision Laboratories, Assistant Clinical Professor, Department of Laboratory Medicine & Pathology, University of Alberta, discuss how amplicon-based NGS panels meet biomarker testing guidelines in practice including routine diagnostics, expanded workup, and copy number variation (CNV) detection.